Lincocin: Potent Gram-Positive Antibiotic Therapy
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.45 | $64.50 (0%) | 🛒 Add to cart |
| 20 | $6.02 | $129.00 $120.40 (7%) | 🛒 Add to cart |
| 30 | $5.42 | $193.50 $162.54 (16%) | 🛒 Add to cart |
| 60 | $3.78 | $387.00 $227.04 (41%) | 🛒 Add to cart |
| 90 | $3.61 | $580.50 $325.08 (44%) | 🛒 Add to cart |
| 120 | $3.44 | $774.00 $412.80 (47%) | 🛒 Add to cart |
| 180 | $3.18 | $1161.00 $572.76 (51%) | 🛒 Add to cart |
| 270 | $2.92 | $1741.50 $789.48 (55%) | 🛒 Add to cart |
| 360 | $2.58
Best per pill | $2322.00 $928.80 (60%) | 🛒 Add to cart |
Synonyms | |||
Lincocin (lincomycin hydrochloride) is a lincosamide antibiotic indicated for the treatment of serious infections caused by susceptible strains of Gram-positive bacteria, particularly in patients who cannot tolerate or have failed first-line therapies like penicillins. Its specialized mechanism of action, binding to the 50S subunit of the bacterial ribosome to inhibit protein synthesis, makes it a critical agent in the infectious disease arsenal. This injectable formulation is reserved for severe clinical scenarios where narrower-spectrum agents are inappropriate or ineffective, requiring administration under strict medical supervision due to its specific indications and potential adverse effect profile.
Features
- Active Ingredient: Lincomycin hydrochloride
- Pharmacologic Class: Lincosamide antibiotic
- Administration Route: Intramuscular (IM) or Intravenous (IV) injection only
- Available Strengths: 300 mg/mL in 2 mL and 10 mL vials
- Mechanism of Action: Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis
- Spectrum of Activity: Primarily effective against Gram-positive aerobes and anaerobes, including streptococci, staphylococci (including some penicillin-resistant strains), and pneumococci
Benefits
- Provides targeted therapy against serious Gram-positive bacterial infections when penicillin-class antibiotics are contraindicated or ineffective
- Demonstrates reliable bactericidal activity against susceptible anaerobic organisms, making it valuable in polymicrobial infections
- Offers flexible administration routes (IM/IV) suitable for both hospital and transitional care settings
- Maintains efficacy in deep tissue infections due to good tissue penetration, including bone
- Serves as an important alternative for patients with documented beta-lactam hypersensitivity
- Supports antimicrobial stewardship by providing a narrow-spectrum option for confirmed Gram-positive infections
Common use
Lincocin is primarily employed in the treatment of severe infections caused by susceptible strains of Gram-positive microorganisms. Its main clinical applications include serious respiratory tract infections such as pneumonia and empyema caused by susceptible streptococci, staphylococci, and pneumococci. It is also indicated for skin and soft tissue infections of severe nature, including cellulitis, abscesses, and wound infections. Additionally, Lincocin finds use in septicemia and endocarditis when caused by susceptible organisms. Its activity against anaerobic bacteria makes it particularly valuable in the treatment of intra-abdominal infections, pelvic inflammatory disease, and other infections involving Bacteroides species and other anaerobic pathogens. The drug is typically reserved for cases where penicillin antibiotics are not suitable due to resistance or allergy.
Dosage and direction
Adult Dosage:
- Serious infections: 600 mg IM every 12-24 hours
- More severe infections: 600 mg IM every 12 hours or more frequently
- IV administration: 600 mg to 1 g every 8-12 hours, diluted in at least 100 mL of appropriate solution and infused over at least 1 hour
- Maximum daily dose: 8 grams
Pediatric Dosage (over 1 month of age):
- 10 mg/kg IM every 12-24 hours
- IV administration: 10-20 mg/kg/day in divided doses every 8-12 hours
- Maximum daily dose: 8 grams
Dosage must be adjusted in patients with significant hepatic impairment. The duration of therapy depends on the severity and type of infection but typically continues for at least 10 days in beta-hemolytic streptococcal infections to prevent rheumatic fever or glomerulonephritis. IM injections should be administered deep intramuscularly, and IV infusions must be given slowly to minimize cardiovascular side effects.
Precautions
Lincocin requires careful patient monitoring throughout therapy. Liver function tests should be performed regularly during prolonged treatment due to potential hepatotoxicity. Renal function should be assessed, particularly in elderly patients or those with pre-existing renal impairment. Complete blood counts are recommended during extended therapy to monitor for possible hematologic abnormalities. Patients should be closely observed for signs of superinfection or pseudomembranous colitis, which may occur during or after antibiotic treatment. Caution is advised when administering to patients with a history of gastrointestinal disease, particularly colitis. The drug may cause neuromuscular blockade, so caution is needed in patients receiving anesthetic agents or neuromuscular blocking agents.
Contraindications
Lincocin is contraindicated in patients with known hypersensitivity to lincomycin, clindamycin, or any component of the formulation. It should not be used in patients with a history of antibiotic-associated colitis, including pseudomembranous colitis. The drug is contraindicated for the treatment of minor bacterial or viral infections such as common upper respiratory infections. Use in newborns (less than 1 month of age) is contraindicated due to immature metabolic and excretory systems. Concomitant use with erythromycin is contraindicated due to potential antagonism.
Possible side effect
Gastrointestinal: Diarrhea (may range from mild to severe pseudomembranous colitis), nausea, vomiting, abdominal pain, glossitis, stomatitis
Hypersensitivity reactions: Skin rashes, urticaria, angioedema, serum sickness, anaphylaxis in rare cases
Hematologic: Neutropenia, leukopenia, thrombocytopenia, agranulocytosis (with prolonged therapy)
Hepatic: Jaundice, liver function test abnormalities
Cardiovascular: Hypotension following rapid IV administration, cardiorespiratory arrest (rare, with too rapid IV infusion)
Local reactions: Pain at injection site, sterile abscess formation with IM injection, thrombophlebitis with IV administration
Other: Vertigo, dizziness, tinnitus, polyarthritis
Drug interaction
Erythromycin: Antagonism may occur; concomitant use is contraindicated Kaolin-pectin: May reduce absorption of orally administered lincomycin Neuromuscular blocking agents: Enhanced neuromuscular blockade may occur Opioid analgesics: May delay gastric emptying and affect absorption of oral lincomycin Chloramphenicol: Possible antagonism; generally not recommended Cyclosporine: May decrease cyclosporine levels, requiring monitoring Oral contraceptives: Possible decreased efficacy of oral contraceptives
Missed dose
If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Maintaining consistent antibiotic blood levels is important for therapeutic efficacy, so healthcare providers should be notified of any missed doses to assess whether adjustment of the treatment schedule is necessary.
Overdose
Symptoms of overdose may include increased severity of common side effects, particularly gastrointestinal symptoms such as severe diarrhea, nausea, and vomiting. Neurological symptoms including dizziness, vertigo, and possible seizures may occur. Significant overdose may potentiate neuromuscular blockade effects. There is no specific antidote for lincomycin overdose. Treatment is supportive and symptomatic, including maintenance of hydration, electrolyte balance, and monitoring of vital signs. Hemodialysis is not effective for removing significant amounts of the drug from circulation due to high protein binding. In cases of suspected overdose, immediate medical attention should be sought.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from light and excessive heat. The solution should be inspected visually for particulate matter and discoloration before administration. Once diluted for IV infusion, the solution should be used within 24 hours when stored at room temperature or within 48 hours if refrigerated. Do not freeze. Keep out of reach of children. Discard any unused portion appropriately according to institutional guidelines for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lincocin is a prescription medication that should only be used under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for complete information regarding indications, dosage, warnings, and precautions. Individual patient response may vary, and appropriate medical supervision is essential throughout treatment. Serious infections require proper diagnosis and monitoring by healthcare providers.
Reviews
“Lincocin has been invaluable in our infectious disease practice for managing serious Gram-positive infections in penicillin-allergic patients. Its targeted spectrum helps avoid broader antibiotic exposure, though we remain vigilant for gastrointestinal side effects.” - Infectious Disease Specialist, 15 years experience
“In orthopedic infections involving susceptible organisms, particularly in penicillin-allergic patients, Lincocin has provided reliable bone penetration and clinical efficacy. The requirement for parenteral administration limits outpatient use, but it remains an important option for hospitalized patients.” - Orthopedic Surgeon
“While effective, Lincocin requires careful patient selection and monitoring. We’ve found it particularly useful for anaerobic infections in abdominal surgery patients who cannot receive beta-lactams. The potential for C. difficile colitis necessitates close observation and patient education about diarrhea symptoms.” - Clinical Pharmacist